Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. News about Lucid centers on its efforts to detect esophageal precancer in patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, using its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
On this page, readers can follow Lucid’s announcements on business updates, financial results, capital-raising activities, and clinical data related to EsoGuard and EsoCheck. Company press releases have highlighted quarterly financial results, the number of EsoGuard tests processed, and revenues associated with those tests, reflecting the commercial adoption of its esophageal precancer detection tools.
Lucid’s news flow also includes developments in reimbursement and coverage, such as Medicare Local Coverage Determination (LCD) processes and Contractor Advisory Committee (CAC) meetings where medical experts have discussed coverage for EsoGuard. The company issues updates on these milestones because they are important for expanding patient access and insurance coverage for its tests.
In addition, Lucid regularly announces participation in investor and industry conferences, business update webcasts, and leadership appointments related to market access and government affairs. Clinical and real-world data updates, including large analyses of EsoGuard and EsoCheck performance in routine practice, are another key component of its news, providing insight into safety, tolerability, technical success, and use in at-risk GERD populations.
Investors and observers can use this news page to track Lucid’s progress as a commercial-stage diagnostics company focused on early detection of esophageal precancer, along with its financial disclosures and strategic communications.
PAVmed (NASDAQ: PAVM) reported its Q4 and full year 2024 financial results, highlighting significant progress across its subsidiaries. Lucid Diagnostics achieved record test volumes with 4,042 EsoGuard tests in Q4 (45% sequential, 84% annual increase) and $1.2 million in revenue. The company secured its first commercial insurance coverage from Highmark Blue Cross Blue Shield.
Veris Health completed a private placement raising $2.4 million at a $35 million pre-money valuation, supplementing a $1.8 million NIH grant. The funds will advance their implantable physiological monitor through FDA clearance.
PAVmed reported Q4 revenues from approximately 125 Veris Cancer Care Platform patients. Operating expenses were $5.2 million, including $0.7 million in stock-based compensation. The company achieved GAAP net income of $1.3 million ($0.12 per diluted share), with non-GAAP adjusted loss of $0.7 million. Cash position stood at $1.2 million, with pro forma cash of $3.6 million including Q1 2025 private placement.
Lucid Diagnostics (NASDAQ: LUCD) reported strong Q4 2024 performance with record 4,042 EsoGuard tests processed, representing a 45% sequential and 84% annual increase. The company recognized $1.2 million in EsoGuard revenue for Q4 2024.
Key achievements include securing over 20 new cash-pay concierge medicine contracts, obtaining first positive commercial insurance coverage from Highmark Blue Cross Blue Shield, and first agreement under state biomarker legislation with BCBS Rhode Island. The company completed a $22 million convertible debt refinancing and $15.3 million common stock financing, extending cash runway.
Financial highlights show Q4 2024 operating expenses of $13.6 million, including $1.2 million in stock-based compensation. GAAP net loss was $11.5 million or $(0.20) per share. Cash position stood at $22.4 million as of December 31, 2024, with pro forma cash of approximately $36.9 million including Q1 2025 financing.
Lucid Diagnostics (LUCD) announced that the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines has updated its recommendations to include esophageal precancer screening. The new guidelines now reference professional society guidelines that recommend non-endoscopic biomarker testing, such as Lucid's EsoGuard® Esophageal DNA Test with EsoCheck® Collection Device, as an acceptable alternative to invasive upper endoscopy for detecting esophageal precancer (Barrett's Esophagus).
This update aligns with the American College of Gastroenterology (ACG) Clinical Guideline and represents a significant step toward recognizing esophageal precancer testing's role in cancer prevention. The company expects this alignment between NCCN Guidelines and gastroenterology society guidelines to positively influence commercial insurance coverage decisions and expand access to EsoGuard testing.
Lucid Diagnostics (Nasdaq: LUCD) announced the acceptance of its ENVET-BE clinical utility study for publication in Gastroenterology & Hepatology, marking the fifth peer-reviewed publication supporting its EsoGuard® Esophageal DNA Test.
The study, examining data from 199 EsoGuard-positive patients who underwent confirmatory upper endoscopy (EGD), demonstrated that EsoGuard significantly improves the detection of esophageal precancer (Barrett's Esophagus or BE). Key findings show:
- 2.4-fold higher diagnostic yield for BE compared to screening EGD alone
- Nearly three-fold higher yield in patients meeting American College of Gastroenterology screening criteria
This research validates EsoGuard as an effective non-invasive triage tool, allowing most at-risk patients to avoid invasive procedures while enhancing the efficiency of endoscopy resource utilization. The study supports ongoing efforts to secure positive commercial insurance coverage policies, following recent success with Highmark Blue Cross Blue Shield.
Lucid Diagnostics (LUCD) has achieved a significant milestone with its first positive commercial insurance coverage for the EsoGuard® Esophageal DNA Test through Highmark Blue Cross Blue Shield in New York state. The regional BCBS plan will cover non-invasive screening of esophageal precancer and cancer for patients meeting established professional society guidelines for testing.
This landmark coverage decision is expected to serve as a precedent for other commercial insurers to follow suit. According to Dr. Lishan Aklog, Lucid's Chairman and CEO, this development validates their clinical evidence base. The company continues to engage with commercial insurers nationwide to expand access to EsoGuard precancer testing.
PAVmed (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for March 25, 2025, at 8:30 AM ET.
During the call, Chairman and CEO Lishan Aklog, M.D., will provide a business update and overview of company operations and growth strategy. President and CFO Dennis McGrath will discuss fourth quarter 2024 financial results.
- U.S. callers can dial 1-800-836-8184
- International callers can dial 1-646-357-8785
- Conference name: 'PAVmed Business Update'
A 30-day replay will be available in the investor relations section at pavmed.com following the call.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has scheduled a business update conference call and webcast for March 24, 2025, at 8:30 AM ET.
During the call, Chairman and CEO Lishan Aklog will provide a comprehensive business update, including the company's operations and growth strategy. CFO Dennis McGrath will present the fourth quarter 2024 financial results.
Investors can access the webcast through the company's investor relations website at luciddx.com. For telephone access:
- U.S. callers: 1-800-836-8184
- International callers: 1-646-357-8785
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has completed its previously announced registered direct offering. The company raised $15.3 million in gross proceeds through the sale of 13,939,331 shares of common stock at $1.10 per share.
The net proceeds, after deducting approximately $0.8 million in placement agent fees and other offering expenses, will be used for working capital and general corporate purposes. Canaccord Genuity served as the sole placement agent for the offering.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has announced a registered direct offering of 13,939,331 shares of common stock at $1.10 per share. The offering is expected to generate $15.3 million in gross proceeds, with approximately $0.8 million in placement agent fees and other expenses.
The offering, managed by sole placement agent Canaccord Genuity, is anticipated to close around March 5, 2025. The company plans to utilize the net proceeds for working capital and general corporate purposes. The securities are being offered through a previously declared effective Form S-3 registration statement.
Lucid Diagnostics (Nasdaq: LUCD) announced that a consortium of academic medical centers has received an $8 million NIH R01 grant for a five-year clinical study of its EsoCheck® and EsoGuard® technologies. The study will evaluate esophageal precancer detection in at-risk individuals without GERD symptoms.
The research, led by investigators from Case Western Reserve University and University Hospitals, will involve 800 patients across five research centers. The study aims to improve Barrett's Esophagus (BE) detection in non-GERD at-risk populations, who account for nearly half of esophageal cancer cases but are currently excluded from screening guidelines.
The study could potentially expand EsoGuard's target population for esophageal precancer testing. The technology was originally developed at CWRU and UH, with Lucid licensing the technologies exclusively in 2018.